Fulcrum Therapeutics Is Becoming a Migraine Drug Company. Here Is How

Fulcrum Therapeutics (Nasdaq: FULC) announced Monday it has entered into a definitive agreement to merge with privately held Slate Medicines in an all-stock transaction. The combined company will operate under the Slate Medicines name and pivot entirely away from Fulcrum’s original rare hematological disease pipeline toward Slate’s portfolio of next-generation migraine therapeutics. Alongside the merger, the companies announced an oversubscribed $245 million private placement from a syndicate of healthcare investors, expected to fund the combined operations into 2029.

This deal follows one of the more difficult stretches in Fulcrum’s history, and understanding that context is essential to understanding why this transaction exists at all. In June, Fulcrum discontinued development of pociredir, its lead drug candidate for sickle cell disease, after the FDA raised concerns about the drug’s benefit-risk profile in a recent meeting. Regulators specifically flagged an unexpectedly high rate of secondary hematologic malignancies observed in patients treated with a chemically related PRC2 inhibitor from another company, a drug that its own manufacturer had voluntarily pulled from shelves worldwide earlier this year. Fulcrum’s stock fell more than 50% on the news, and the company subsequently laid off 48 of its 57 employees, roughly 85% of its workforce, while beginning a formal review of strategic alternatives that included a merger, business combination, or other transaction. As of March 31, Fulcrum held $333.3 million in cash and marketable securities, enough runway to keep the company operating into 2029 on its own. Separately, and worth noting for full transparency, a law firm publicly announced last week it is investigating potential securities law violations tied to Fulcrum’s disclosures around the pociredir discontinuation. That investigation is ongoing and its outcome, if any, is not yet known.

Slate’s lead candidate, SLTE-1009, is a clinical-stage subcutaneous monoclonal antibody targeting PACAP and VIP pathways, developed as a potentially best-in-class preventative treatment for migraine. Migraine remains a large and underserved therapeutic market, and antibody-based preventative treatments targeting neuropeptide pathways have become one of the more actively pursued mechanisms in the space over the past several years.

A Familiar Small Cap Biotech Pattern

This transaction follows a structure we have covered before on ChannelChek: a publicly traded biotech whose original clinical program failed, leaving it with a Nasdaq listing, meaningful cash reserves, and no viable path forward on its own, becomes the vehicle through which a well-funded private biotech gains public market access without pursuing a traditional IPO. Rather than navigating the lengthy IPO process independently, Slate secures a public listing, a syndicate of institutional capital, and immediate resources to advance its lead asset, all in a single coordinated transaction.

For investors tracking this space, the Fulcrum-Slate combination is a useful reminder that a failed clinical trial does not automatically end a company’s story, particularly when meaningful cash remains on the balance sheet. It also underscores a genuine risk worth weighing carefully: shareholders who bought into Fulcrum’s original rare disease thesis are now effectively invested in an entirely different company, pursuing an unrelated therapeutic area, following a transaction that arrives while questions about the prior program’s disclosures remain unresolved. Reverse mergers of this type can create real value when the incoming asset is genuinely differentiated, but investors should evaluate the new company on its own clinical and commercial merits rather than assuming continuity with the business they originally invested in.

Xcel Brands (XELB) – Commercialization Advances: Building Toward a Second-Half Revenue Inflection


Monday, August 17, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

George Proost, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q2 results were softer than expected, largely due to timing. Revenue was approximately $1.1 million, compared with $1.3 million in the prior-year period, reflecting the Judith Ripka divestiture and delays associated with QVC’s bankruptcy and vendor-credit issues. Importantly, the QVC-related disruptions appear to have largely been resolved.

Commercialization remains the key story as the creator portfolio moves into the market. With the portfolio’s social media reach having expanded from roughly 5 million to more than 46 million followers, we believe the company has assembled a compelling audience from which to build consumer brands. The next several quarters should provide evidence regarding Xcel’s ability to convert that audience into sustainable royalty revenue.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Star Equity Holdings, Inc. (STRR) – Second Quarter Results And An Acquisition


Monday, August 17, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Overview. In the second quarter, Business Services delivered modest revenue growth, with gross profit down slightly year-over-year, while Energy Services posted strong year-over-year gains in revenue, gross profit, and adjusted EBITDA, reflecting activity increases and new client wins in the geothermal and mining industries. Building Solutions remained below management expectations due to market softness and contract timing.

2Q26 Results. Second quarter 2026 revenue was $54.9 million versus a pro forma $59.2 million in 2Q25. We were at $64 million. The delta was in Building Solutions, which continues to operate in a challenging environment. Adjusted EBITDA was $2.2 million versus a pro forma $8.5 million, which included a $5.5 million gain. Star reported an adjusted loss of $0.15/sh in 2Q26 compared to EPS of $0.20/sh in 2Q25.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Euroseas (ESEA) – Second Quarter 2026 Review and Outlook


Monday, August 17, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Second Quarter Financial Results. Euroseas Ltd. reported solid second quarter 2026 financial performance supported by elevated charter rates, high fleet utilization, and disciplined cost management. While net revenues declined modestly to $56.5 million compared to $57.2 million in the prior year period due to a smaller average fleet size, adj. EBITDA increased to $40.1 million compared to $39.3 million during the second quarter of 2025, and adj. earnings per share increased to $4.70 from $4.20. We had projected net revenue of $56.5 million and adj. EBITDA of $40.1 million. 

Outlook Remains Constructive. In our viewthe near-term outlook remains positive, supported by strong charter rates, tight vessel availability in the feeder and intermediate segments of the containership market, and significant charter coverage through 2027. While market conditions could moderate as the supply of vessels increases and Red Sea routes potentially normalize, we think the feeder and intermediate segments are relatively well positioned versus larger vessel classes. Euroseas’ strong charter coverage of 96.0% in 2026, 81.3% in 2027, and 46.8% in 2028 is expected to insulate the company from any volatility in the market.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

DLH Holdings (DLHC) – More Contract Movement


Monday, August 17, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New ID/IQ. According to the Department of War’s daily contract award notifications, DLH has been named to the Naval Information Warfare Center Pacific’s recent ID/IQ to provide operational exercise design and construction, operations and requirements analysis, concept formulation and development, feasibility demonstrations, and operational and technical support. This includes efforts to analyze and engineer operational, functional, and system requirements to establish national, theater, and force-level architecture. Additional efforts will include requirements verification and validation, engineering analysis, technical documentation, software and hardware design and implementation, as well as systems integration, test and evaluation, and demonstration. This is the second major ID/IQ to which DLH has been named recently.

Details. The contracting vehicle is a $278 million indefinite-delivery/indefinite-quantity, multiple-award contract with cost-plus-fixed-fee and cost-no-fee pricing. This seven-year contract includes one two-year option which, if exercised, would bring the potential value of this contract to $400 million. The period of performance is Aug. 12, 2026, through Aug. 12, 2031. DLH will have the opportunity to compete for task orders during the ordering period.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Cadrenal Therapeutics (CVKD) – 2Q26 Reported With Review Of New “Three Pillars” Strategy


Monday, August 17, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

2Q26 Reported With Review Of New Strategy and Product Data. Cadrenal reported a 2Q26 loss of $3.3 million, or $(1.14) per share. The company modified its strategy and plans to develop its products through collaborations, out-licensing agreements, and non-dilutive grants to conserve capital resources. On June 30, 2026, cash and cash equivalents were $4.2 million, excluding proceeds from the private placement completed July 1. The private placement raised about $3.0 million, with warrants that could raise another $5.8 million upon exercise.

The Pipeline Has Been Reorganized Into “Three Pillars”.  The company has divided the pipeline into products for Cardiac Acute Critical Care, Orphan Diseases, and Post-Operative Care. These divisions emphasize how the products can address important needs before and after cardiac surgery, as well as for patient populations with few options.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

ACCO Brands (ACCO) – Further Expansion into Accessories


Monday, August 17, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Trust Acquisition. On Friday, ACCO announced it has entered into a definitive agreement to acquire Trust, a European provider of computer and gaming accessories. The transaction is valued at approximately $57 million. The transaction will be financed through borrowings under ACCO’s revolving credit facility, with limited impact on pro forma leverage. The transaction is expected to close in late third quarter or early fourth quarter.

Who is Trust? Founded in 1983 and headquartered in the Netherlands, Trust is a well-recognized consumer electronics brand with more than 40 years of presence in PC accessories, gaming, smart home, and mobile accessories. The company offers a comprehensive product portfolio spanning keyboards, mice, headsets, speakers, webcams, chargers, and gaming peripherals, sold through a broad network of leading retailers, e-commerce platforms, and B2B channels. Trust operates an asset-light model with outsourced manufacturing and scalable sourcing and serves customers in Europe and Latin America.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Everyone Sees the Small Cap Rally. Almost No One Is Buying It

Small-cap stocks just delivered their best first half on record, and almost nobody is talking about where the money went next.

U.S. small caps returned 22.93% in the first half of 2026, outpacing large caps at 9.55% by the widest margin in history for that stretch. It is the kind of number that normally sends investors scrambling to add exposure. Yet the flow of capital into small-cap funds tells a different story, one that raises an obvious question: if small caps are winning this decisively, why hasn’t the money followed?

The data shows a real disconnect. Small-cap ETFs pulled in roughly $7 billion during the first half of the year. Large-cap ETFs, by comparison, absorbed $309 billion over the same period. On the mutual fund side, small-cap funds have seen about $8 billion in net inflows year to date, a modest turnaround after $8 billion in outflows the year before. Actively managed small-cap funds have fared even worse, continuing to lose assets as investors keep shifting toward passive strategies more broadly.

In other words, small caps are outperforming while investors remain largely on the sidelines. That gap between performance and participation is unusual, and some market strategists see it as meaningful. State Street has pointed to the lag as a sign the rally may have room to keep running, arguing that a rotation this significant with so little capital chasing it is not the profile of a crowded trade. If allocators eventually catch up to the performance numbers, the argument goes, the current move could extend further rather than reverse.

Not everyone is convinced. BlackRock has reportedly kept a more cautious stance on small caps as a group, citing ongoing uncertainty around financing conditions and the broader macro backdrop. Smaller companies tend to carry more floating-rate debt and less balance sheet cushion than their large-cap counterparts, which makes them more sensitive to shifts in interest rates and credit availability. That sensitivity cuts both ways. It can amplify gains when conditions turn favorable, but it can just as easily amplify losses if the environment shifts.

There is also a more speculative data point worth noting with some caution. MoneyFlows, a firm that tracks proprietary money-flow signals, claims that nearly 98% of its tracked equity inflows this year have gone into companies with market capitalizations under $300 billion, which it frames as evidence of institutional accumulation building beneath the surface. Unlike the ETF and mutual fund flow data from sources such as Morningstar and State Street, this is a promotional research product, and the claim should be weighed accordingly.

What is clear is that small caps have already made their move on performance. Whether capital flows catch up, stall, or reverse from here may say more about the durability of this rally than the first-half numbers themselves. For investors watching the space, the next few months of fund flow data could matter as much as the earnings results that got small caps here in the first place.

The Fed’s September Decision Comes Down to One Number Nobody Has Seen Yet

Federal Reserve officials gather in Jackson Hole in two weeks for a symposium that arrives at a genuinely pivotal moment for the central bank. All eyes will be on Chair Kevin Warsh’s first speech in that role, historically a venue Fed chairs use to set the table for upcoming policy decisions or signal structural shifts in approach. This year, the stakes are higher than usual, following a July 29 meeting that left markets confused and a policy committee that appears genuinely divided.

At that meeting, the Fed held rates steady at 3.50% to 3.75% for a fifth consecutive session, as expected. What rattled markets was Warsh’s press conference performance, where he repeatedly deflected questions about why the Fed was not raising rates and suggested that rising bond yields themselves were doing some of the Fed’s tightening work. Markets responded by aggressively pricing in more than two rate hikes in the weeks that followed, alongside genuine uncertainty about whether the committee has a coherent strategy at all.

Since that meeting, the incoming data has offered modest relief. Core CPI rose 2.5% year over year in July, marking a second consecutive month of cooling from 2.6% in June and 2.9% in May. Producer price data told a more mixed story. Core PPI, excluding food, energy, and trade services, rose 4.7% year over year, slightly hotter than expected though down from June’s 5.1% pace, while the monthly reading cooled to 0.2% from an upwardly revised 0.4% in June.

Both figures feed into the Personal Consumption Expenditures price index, the Fed’s preferred inflation gauge, due for release August 26, just days before the Jackson Hole gathering. Economists estimate core PCE rose somewhere between 0.16% and 0.3% in July, a range wide enough that it genuinely could push the committee in either direction.

The range of professional forecasts illustrates just how unresolved this debate is. Some economists estimate July’s core PCE reading held firm enough to keep the annual rate sticky near 3.3%, arguing that could actually harden the resolve of policy hawks rather than ease it. Others view the broader disinflation trend, tied to fading tariff effects and easing oil prices following the resolution of Strait of Hormuz disruptions, as evidence the Fed can remain patient through year-end, while still leaving the door open to tightening if price pressures reaccelerate. A third camp sees the data pointing toward a soft enough reading to pull the three-month annualized core PCE rate down to 2.5%, which would make a September hike look considerably less likely than markets currently expect.

That range of outside opinion mirrors a genuine split inside the Fed itself. Cleveland Fed President Beth Hammack, who dissented in favor of a hike at the July meeting, has continued arguing publicly that more than one rate increase is needed to bring inflation fully under control. Meanwhile, New York Fed President John Williams has suggested that if monthly core PCE consistently prints around 0.2% through the second half of the year, it would signal inflation returning to target on its own, without further tightening. Former Atlanta Fed President Dennis Lockhart, now outside the institution, has cautioned that one or two encouraging months of data is not persuasive evidence that underlying inflation pressure, elevated for more than five years, is genuinely breaking, particularly with the labor market still near full employment.

For companies operating below the $2 billion market cap threshold, this unresolved debate matters directly. Small and microcap companies carry disproportionately more variable-rate debt than large cap peers, making their borrowing costs highly sensitive to exactly the kind of uncertainty currently surrounding the Fed’s next move. The market will receive one more full month of inflation data, including the volatile August CPI report, before the September meeting itself, meaning the path forward remains almost entirely data-dependent. Warsh’s Jackson Hole speech will be the first real signal of how he is weighing that data, and small cap investors watching the cost of capital heading into the fall would do well to treat it as required listening.

Xcel Brands (XELB) – Creator-Commerce Strategy Advances Despite Slower Revenue Ramp


Friday, August 14, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

George Proost, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q2 results reflect a slower-than-anticipated revenue ramp, but underlying operating trends improved. Second quarter revenue of $1.1 million was below our $1.8 million estimate, largely reflecting the timing of the company’s creator-led brand commercialization and the divestiture of Judith Ripka. Importantly, adjusted EBITDA improved sequentially to a loss of $479,000 from roughly $700,000 in Q1, representing a 32% improvement, as illustrated in Figure #1 Q2 Results. 

Creator-led brands begin to contribute; commercialization remains the key catalyst. Management attributed the improved adjusted EBITDA performance in part to product launches from two of its new influencer-led brands. We believe Xcel is transitioning from the investment and incubation phase of its transformation toward commercialization, with Jenny Martinez, Gemma Stafford, Cesar Millan, Coco Rocha, Christie Brinkley, and Longaberger providing multiple opportunities to expand product categories and distribution.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

SKYX Platforms (SKYX) – Another Quarter of Growth


Friday, August 14, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Overview. SKYX Platforms just completed its 10th consecutive quarter of year-over-year growth. The Company is trending positively, generating record second quarter 2026 revenues. The Company’s builder and hotel segments are continuing to grow. With savings of up to 90% of time for installation or renovation, and up to 90% of the cost of renovation and installations, we believe SKYX’s value proposition is very strong in the hotels and builders segments. We believe the positive trends will continue to accelerate through the balance of 2026 as the Company continues to build out and execute on its channel strategy.

2Q26 Results. Revenue in 2Q26 rose 9.6% y-o-y to $25.27 million and was above our $24 million projection, with the increase due to an expansion of sales of SKYX products. The Company reported an adjusted EBITDA loss of $3.5 million, up slightly from last year’s $2.6 million loss. Net loss totaled $8.48 million, or $0.06/sh, versus a $9.1 million net loss, or $0.08/sh, in 2Q25.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Sky Harbour Group (SKYH) – Solid Second Quarter Results


Friday, August 14, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Overview. During the second quarter, the pace of investment and new construction at Sky Harbour continued to accelerate. Assets under construction and completed construction reached over $393 million, a $65 million increase year-to-date and the highest in six months in corporate history.

2Q26 Results. Sky Harbour 2Q26 revenue of $9.86 million rose nearly 50% y-o-y, driven by new campus openings in the past year and increases in occupancy and rental rates. Adjusted EBITDA improved to approximately negative $0.9 million in the second quarter of 2026 from a loss of $3.0 million in the second quarter of 2025. The Company reported a net loss of $1.2 million, or $0.04/sh, versus net income of $17.5 million, or $0.18/sh, in 2Q25, which was positively impacted by $21.8 million of unrealized gain on warrants.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Saga Communications (SGA) – Investment Spending Weighs On Margins


Friday, August 14, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

George Proost, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q2 exceeded expectations. Revenue declined 6.5% year over year to $26.4 million, beating our estimate of $25.5 million by 3.5%. Additionally, adj. EBITDA of approximately $1.1 million compared favorably with our $0.1 million estimate. The beat reflected growth in blended digital revenue, which cushioned double-digit declines across the traditional broadcast business. 

Digital continues to scale. Blended digital offering grew 60.8% during the quarter and was up 76.4% for the first 6 months of the year. Digital reached 19% of gross revenue in the first half compared with 14% a year ago. Management has brought search capabilities in-house with three dedicated specialists, hired and trained ten digital campaign managers, and migrated digital fulfillment to a new platform. In our view, the pace of blended digital growth is the most encouraging development in the quarter and the clearest evidence that the multi-year platform build is beginning to convert.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.